Monoclonal antibody · Agonist of CD40 · developed by Celldex Therapeutics
CDX-1140 is a fully human IgG2 agonistic monoclonal antibody that binds CD40, a tumor necrosis factor receptor superfamily member expressed on dendritic cells, macrophages, B-cells and a range of tumor cells. It activates CD40-dependent signaling, promoting antigen-presenting cell activation and T-cell activation. It is being studied in ovarian, fallopian tube and peritoneal carcinomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05231122 | Phase 2 | Ovarian Clear Cell Adenocarcinoma | Recruiting | CLDX |
| NCT04536077 | Phase 2 | Pancreatic Cancer | Terminated | CLDX |
| NCT04491084 | Phase 1/2 | Non Small Cell Lung Cancer | Terminated | CLDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube Serous AdenocarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Primary Peritoneal Clear Cell AdenocarcinomaRecurrent Primary Peritoneal Endometrioid Adenocarcinoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.
See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLDX catalysts and pipeline →